Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T16:21:22.984Z.
Calculation as of: 2026-10-06T16:21:22.984Z.
Quote observation: 2026-10-06T16:20:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 16291309013886a388882617e5d80f34fb5e9972494eca64a5e5fc74bed8c75f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Benitec Biopharma Inc.
Market Cap
$304.21M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$296.59M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$309.71M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$287.88M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$288.21M
Operating Cash Flow Yield
N/A
TTM Avg
1.81%
3Y Avg
1.81%
5Y Avg
1.81%
Market Cap
$288.33M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$286.75M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$282.68M
Operating Cash Flow Yield
N/A
TTM Avg
1.84%
3Y Avg
1.84%
5Y Avg
1.84%
Market Cap
$285.37M
Operating Cash Flow Yield
N/A
TTM Avg
41.23%
3Y Avg
41.23%
5Y Avg
41.23%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | $304.21M | N/A | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $296.59M | N/A | N/A | N/A | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $309.71M | N/A | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $287.88M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.21M | N/A | 1.81% | 1.81% | 1.81% |
| Sagimet Biosciences Inc. (SGMT)vs › | $288.33M | N/A | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $286.75M | N/A | N/A | N/A | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $282.68M | N/A | 1.84% | 1.84% | 1.84% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $285.37M | N/A | 41.23% | 41.23% | 41.23% |
| C4 Therapeutics, Inc. (CCCC)vs › | $319.54M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
